Filing Flows › Regen BioPharma (RGBP) › Recalls, complaints & regulation
Regen BioPharma (RGBP): EPA violations
Regen BioPharma (RGBP) beyond its filings: 0 EPA-regulated facilities in violation, $246K in penalties over five years.
Regen BioPharma's latest quarter
Regen BioPharma, Q3 FY26: revenue $59K (0% year over year), operating margin 41.5%, net loss $638K, operating cash flow −$24K. The chart follows the revenue to costs, profit and cash.
Questions
Has Regen BioPharma been fined by the EPA?
The 4 EPA-regulated facilities on file under its name drew $246K in penalties over five years; 0 are in violation now.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.